Sitagliptin + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Jul 1, 2012 → Aug 1, 2013
NCT ID
NCT01600703About Sitagliptin + Placebo
Sitagliptin + Placebo is a phase 2/3 stage product being developed by Merck for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01600703. Target conditions include Hyperlipidemia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02536248 | Phase 3 | Completed |
| NCT02256189 | Approved | Completed |
| NCT02294084 | Approved | Completed |
| NCT02015910 | Approved | Terminated |
| NCT01928199 | Approved | Completed |
| NCT01859793 | Approved | Completed |
| NCT01600703 | Phase 2/3 | Completed |
| NCT01334229 | Phase 3 | Completed |
| NCT01272583 | Pre-clinical | Completed |
| NCT00790205 | Phase 3 | Completed |
| NCT00732121 | Approved | UNKNOWN |
| NCT00660075 | Phase 3 | Completed |
| NCT00501657 | Phase 1 | Completed |
Competing Products
20 competing products in Hyperlipidemia